<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02120690</url>
  </required_header>
  <id_info>
    <org_study_id>TNS-FMA</org_study_id>
    <nct_id>NCT02120690</nct_id>
  </id_info>
  <brief_title>Trigeminal Nerve Stimulation (TNS) in the Treatment of Fibromyalgia</brief_title>
  <acronym>TNS-FMA</acronym>
  <official_title>Trigeminal Nerve Stimulation (TNS) as a Complementary Strategy in the Treatment of Fibromyalgia, Open Label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santa Casa Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santa Casa Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To the investigators knowledge there are no studies of Trigeminal Nerve Stimulation (TNS) for
      fibromyalgia. TNS may modify overlapping mood and fibromyalgia pain regulation circuitry. The
      investigators hypothesized that patients with fibromyalgia might experience a clinically
      significant reduction in daily pain if investigators were to administer TNS in a manner
      similar to experimental antidepressant protocols.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS for pain</measure>
    <time_frame>10 day-follow up</time_frame>
    <description>Comparison between VAS for pain after intervention protocol and baseline score</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Trigeminal nerve stimulation - active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10-day TNS interventional protocol over an 10-day follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trigeminal nerve stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>10-day sham interventional protocol over an 10-day follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Trigeminal nerve stimulation</intervention_name>
    <description>10-day TNS interventional protocol over an 10-day follow-up. Subjects will have electrodes (Superior Silver 1.25-in. diameter) placed on their foreheads to stimulate the V1 branches of the trigeminal nerve bilaterally for approximately 30 minutes each day. Current was adjusted to maintain comfortable but perceptible levels of stimulation</description>
    <arm_group_label>Trigeminal nerve stimulation - active</arm_group_label>
    <arm_group_label>Trigeminal nerve stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  We will adopt the following inclusion criteria: (1) patients between 18 and 69 years;
             (2) patients with a diagnosis of fibromyalgia according to a trained phisycian; (3)
             score greater than or equal to 5 on the VAS for pain; (4) agreement to participate in
             the study as recommended in the IC.

        Exclusion Criteria:

          -  Exclusion criteria we cite: (1) patients with psychiatric hospitalization indicated;
             (2) patients with psychiatric comorbidity; (3) patients with a diagnosis of
             personality disorder; (4) presence of severe neurological or medical diseases such as
             neoplasms in activity, neurodegenerative diseases and chronic decompensated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Shiozawa, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Neuromodulation Laboratory - Santa Casa Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcelo V Perez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anestesiology - ISCMSP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Quirino Corderio, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Psychiatry - ISCMSP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro de Atencao Integrada à Saúde Mental</name>
      <address>
        <city>sao Paulo</city>
        <state>sP</state>
        <zip>04017030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pedro Shiozawa, MD</last_name>
      <phone>55 11 34662100</phone>
      <email>pedroshiozawa@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Pedro Shiozawa</last_name>
    </contact_backup>
    <investigator>
      <last_name>Pedro Shiozawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Collado A, Conesa A. [Pharmacologic treatment of fibromyalgia: Towards chemical neuromodulation]. Reumatol Clin. 2009 Aug;5 Suppl 2:27-31. doi: 10.1016/j.reuma.2009.04.003. Epub 2009 Jul 9. Spanish.</citation>
    <PMID>21794655</PMID>
  </reference>
  <reference>
    <citation>Tzabazis A, Aparici CM, Rowbotham MC, Schneider MB, Etkin A, Yeomans DC. Shaped magnetic field pulses by multi-coil repetitive transcranial magnetic stimulation (rTMS) differentially modulate anterior cingulate cortex responses and pain in volunteers and fibromyalgia patients. Mol Pain. 2013 Jul 2;9:33. doi: 10.1186/1744-8069-9-33. Erratum in: Mol Pain. 2014;10:16.</citation>
    <PMID>23819466</PMID>
  </reference>
  <reference>
    <citation>Short EB, Borckardt JJ, Anderson BS, Frohman H, Beam W, Reeves ST, George MS. Ten sessions of adjunctive left prefrontal rTMS significantly reduces fibromyalgia pain: a randomized, controlled pilot study. Pain. 2011 Nov;152(11):2477-84. doi: 10.1016/j.pain.2011.05.033. Epub 2011 Jul 20.</citation>
    <PMID>21764215</PMID>
  </reference>
  <reference>
    <citation>Ozgocmen S, Yoldas T, Kamanli A, Yildizhan H, Yigiter R, Ardicoglu O. Auditory P300 event related potentials and serotonin reuptake inhibitor treatment in patients with fibromyalgia. Ann Rheum Dis. 2003 Jun;62(6):551-5.</citation>
    <PMID>12759293</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2014</study_first_submitted>
  <study_first_submitted_qc>April 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2014</study_first_posted>
  <last_update_submitted>April 22, 2014</last_update_submitted>
  <last_update_submitted_qc>April 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Santa Casa Medical School</investigator_affiliation>
    <investigator_full_name>Pedro Shiozawa</investigator_full_name>
    <investigator_title>Coordinator - Laboratory of Clinical Neuromodualtion</investigator_title>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>fibromyagia</keyword>
  <keyword>TNS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

